In the second quarter, Bora Pharmaceuticals reaped substantial profits, driven by gains from its acquisition of the U.S.-based USL Pharmaceuticals. The company reported after-tax net income of NT$12.14 billion for the quarter, marking a 73% year-over-year increase. This translated to earnings per share (EPS) of NT$11.61. For the first half of the year, Bora’s EPS reached NT$18.68, solidifying its position as the most profitable biotech stock.
Read more
